StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Kesimpta (ofatumumab by Quarter

Kesimpta (ofatumumab — self-administered B-cell antibody therapy for relapsing multiple sclerosis RMS) ($M)

QuarterlyAnnual

Novartis Kesimpta (ofatumumab: $1,484M in Q3 2026, up 21.4% from a year earlier. That is the highest of the 23 quarters on record here.

Latest, Q3 2026
1,484
Period ended Sep 30, 2026
Change on a year earlier
+21.4%
1,222 in Q3 2025
History
23 quarters
Since Q4 2020
Sources
19
Documents cited below

Where the Q3 2026 figure comes from

“|| Kesimpta | 1 484 | 1 222 | 21 | 22”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKesimpta (ofatumumab — self-administered B-cell antibody therapy for relapsing multiple sclerosis RMS) ($M)Year on yearSource
Q3 2026Sep 30, 20261,484+21.4%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20261,424+32.2%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 20261,164+29.5%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20251,228+29.3%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20251,222+45.8%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 20251,077+34.8%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025899+41.1%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024950+48.2%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024838+27.5%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024799+63.4%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024637+65.9%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023641+73.7%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023657+127.3%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023489+104.6%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023384+96.9%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022369+151.0%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up kesimpta (ofatumumab

Cite this data

StockData. (2026). Novartis Kesimpta (ofatumumab ($M), quarterly Q4 2020–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kesimpta

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.